Hydralazine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Hydralazine and local guidelines before prescribing.
Mechanism
Direct arterial vasodilator.
Uses
Hypertensive emergencies in pregnancy, resistant hypertension, heart failure with nitrates.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Headache, tachycardia, fluid retention, lupus-like syndrome.
Interactions
Beta-blockers limit reflex tachycardia; additive hypotension.
Contraindications and cautions
SLE, severe tachycardia, aortic stenosis
Monitoring
BP, ANA if long term
Pregnancy and breastfeeding
Used in pregnancy
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
Slow acetylators have higher lupus risk; avoid in SLE.
More from the textbook: uses, cautions and other points
- Afterload - the resistance the ventricle pumps against (aortic pressure, systemic vascular resistance, aortic stenosis); reduced by vasodilators (ACE inhibitors, hydralazine, dihydropyridines).
Cardiology: Anatomy Physiology and Pharmacology - Severe pre-eclampsia / eclampsia | Below 160/105 (and 150/100 maintenance); labetalol, nifedipine or hydralazine; magnesium sulfate for seizures
Cardiology: Cardiology Emergencies - Hydralazine with nitrate: May be considered in selected patients who cannot tolerate RAAS-blocking therapies or in specific specialist populations.
Cardiology: Heart Failure › 2.27 🧬 Specialist and Advanced Heart Failure Treatment - Additional options: Ivabradine (sinus rhythm, heart rate ≥75/min, LVEF ≤35%), IV iron for iron deficiency, hydralazine/nitrate where ACE inhibitor/ARB/ARNI cannot be used.
Cardiology: Cardiomyopathies › 3.15 DCM: Management and Prognosis - Treatment before delivery: Beta blocker (e.g. metoprolol), loop diuretic for congestion, hydralazine and nitrates for afterload reduction; avoid ACE inhibitors, ARBs, ARNIs, MRAs and SGLT2 inhibitors. Urgent pregnancy heart team input for timing and mode of delivery.
Cardiology: Cardiomyopathies › 3.42 Peripartum Cardiomyopathy (PPCM) - Drugs causing lupus-like pleurisy (hydralazine, procainamide, isoniazid) | Pleuritis and effusions
Respiratory: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Cardiology: Cardiology Emergencies (1 mention)
- Cardiology: Heart Failure (1 mention)
- Cardiology: Cardiomyopathies (2 mentions)
- Respiratory: Anatomy, Physiology and Pharmacology (1 mention)
- Endocrinology: Adrenal Disease (1 mention)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Renal: Glomerular Disease (1 mention)
- Obstetrics (1 mention)
- Obstetrics: Obstetrics: Emergencies (3 mentions)
- Obstetrics: Medical Problems (3 mentions)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (1 mention)
- Rheumatology: assessment, investigations and drugs (3 mentions)
- Rheumatology: Connective tissue diseases (3 mentions)
- Rheumatology: Vasculitis, GCA and PMR (3 mentions)
- Clinical pharmacology and prescribing: Principles of clinical pharmacology (2 mentions)
- Clinical pharmacology and prescribing: Safe prescribing, prescription writing and medicines law (2 mentions)
- Clinical Immunology: Autoimmunity, autoantibodies and complement (4 mentions)
- Integrated cardiology chapter (3 mentions)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)